Eli Lilly & Co. closed 13.93% short of its 52-week high of $972.53, which the company reached on August 22nd.

Discover why Eli Lilly and Company is set for a strong 2024 with a robust pipeline, solid financials, and strategic growth ...

Eli Lilly Chief Executive David Ricks annual compensation rose to $29.2 million in 2024, a 10% increase from the $26.2 million he received a year earlier. Ricks' payout included $19.7 million in ...

"Eli Lilly Introduces New Weight Loss Drug Doses, Lowers Price Points," at 7:36 a.m. incorrectly said Zepbound also comes in 10 and 12.5 milligram vials. We sell different types of products and ...

Dow Jones futures fell slightly Wednesday morning ... Dow giant Caterpillar fell on an earnings miss, while S&P 500 play Eli Lilly tumbled. But techs rose as Google-parent Alphabet jumped more ...

Eli Lilly (LLY) concluded the recent trading session at $822.51, signifying a -0.27% move from its prior day's close.

The Dow Jones tumbled 500 points as tariff woes resurfaced. Nvidia stock and Tesla sold off on the stock market today.

Fear, uncertainty, and doubt have become the norm in early 2025 with rising stock market volatility. David Jagielski (Eli ...

"Eli Lilly to Offer Higher Doses of Obesity Drug Zepbound at Discounted Prices," at 9:33 a.m. ET, incorrectly said his surname was Johnson. About Dow Jones Newswires Dow Jones Newswires is a ...

Eli Lilly (LLY) has launched its weight-loss and diabetes drug, Mounjaro (tirzepatide), in India, securing a first-mover advantage in a market with a large obese population. This move positions ...

Eli Lilly LLY-0.27%decrease; red down pointing triangle is expanding its offerings of its hit weight-loss drug Zepbound for people who want to pay cash instead of using their health plans ...